Pollypills with or without aspirin in person without cardiovascular disease
The prevalence of the cardiovascular disease is dramatically increasing with about 18 million deaths per year globally; the leading causative but modifiable risk factors...
Category: Dyslipidemia
Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes
Previous cardiovascular outcome trials (CVOTs) suggest that greater benefit might be derived to Asians with newer classes of antihyperglycemic medications as compared to Whites....
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular (CV) diseases. This may be due to a chronic inflammatory state in...
The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality
Proteinuria or albuminuria are used as tools to screen for chronic kidney disease. Their elevated levels are associated with increased risk of progression to...
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial
It has been known that high-fructose consumption increases hepatic de novo lipogenesis and hepatic fat content. Additionally, it reduces hepatic insulin sensitivity independently from...
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2
Hepatorenal syndrome (HRS) is known for poor prognosis. HRS type 1 is characterized by rapid loss of renal function, while chronic ascites and more...
